Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral SCY-078 as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris

Trial Profile

Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral SCY-078 as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Ibrexafungerp (Primary)
  • Indications Candidaemia; Candidiasis
  • Focus Therapeutic Use
  • Acronyms CARES
  • Sponsors SCYNEXIS
  • Most Recent Events

    • 04 Dec 2017 Status changed from planning to recruiting.
    • 15 Nov 2017 New trial record
    • 07 Nov 2017 According to a SCYNEXIS media release, patient enrollment is expected to commence in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top